

RESEARCH PAPER

Receptor activity modifying proteins (RAMPs) interact with the VPAC₂ receptor and CRF₁ receptors and modulate their function

D Wootten^{1*}, H Lindmark^{2†}, M Kadmiel³, H Willcockson³, KM Caron³, J Barwell¹, T Drmota^{2‡} and DR Poyner¹

¹School of Life and Health Sciences, Aston University, Birmingham, UK, ²Department of Lead Generation, AstraZeneca R&D, Mölndal, Sweden, and ³Department of Cellular and Molecular Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Correspondence

David R Poyner, School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK. E-mail: D.R.Poyner@aston.ac.uk

Current address: *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052 Australia; †Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden; ‡R&I iMED, AstraZeneca R&D, Mölndal, Sweden.

Keywords

receptor activity-modifying proteins (RAMPs); RAMP1; RAMP2; RAMP3; VPAC₂ receptor; CRF₁ receptor; *Ramp2*^{−/−} mice; G-protein coupling; biased agonism

Received

10 July 2012

Revised

15 August 2012

Accepted

28 August 2012

BACKGROUND AND PURPOSE

Although it is established that the receptor activity modifying proteins (RAMPs) can interact with a number of GPCRs, little is known about the consequences of these interactions. Here the interaction of RAMPs with the glucagon-like peptide 1 receptor (GLP-1 receptor), the human vasoactive intestinal polypeptide/pituitary AC-activating peptide 2 receptor (VPAC₂) and the type 1 corticotrophin releasing factor receptor (CRF₁) has been examined.

EXPERIMENTAL APPROACH

GPCRs were co-transfected with RAMPs in HEK 293S and CHO-K1 cells. Cell surface expression of RAMPs and GPCRs was examined by ELISA. Where there was evidence for interactions, agonist-stimulated cAMP production, Ca²⁺ mobilization and GTPγS binding to G_s, G_i, G₁₂ and G_q were examined. The ability of CRF to stimulate adrenal corticotrophic hormone release in *Ramp2*^{−/−} mice was assessed.

KEY RESULTS

The GLP-1 receptor failed to enhance the cell surface expression of any RAMP. VPAC₂ enhanced the cell surface expression of all three RAMPs. CRF₁ enhanced the cell surface expression of RAMP2; the cell surface expression of CRF₁ was also increased. There was no effect on agonist-stimulated cAMP production. However, there was enhanced G-protein coupling in a receptor and agonist-dependent manner. The CRF₁ : RAMP2 complex resulted in enhanced elevation of intracellular calcium to CRF and urocortin 1 but not sauvagine. In *Ramp2*^{−/−} mice, there was a loss of responsiveness to CRF.

CONCLUSIONS AND IMPLICATIONS

The VPAC₂ and CRF₁ receptors interact with RAMPs. This modulates G-protein coupling in an agonist-specific manner. For CRF₁, coupling to RAMP2 may be of physiological significance.

Abbreviations

ACTH, adrenal corticotrophic hormone; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; CTR, calcitonin receptor; GLP-1, glucagon-like peptide 1; HA, haemagglutinin; RAMP, receptor activity modifying proteins; PACAP, pituitary AC-activating peptide; PHM-27, peptide histidine methionine-27; VIP, vasoactive intestinal polypeptide; WT, wild-type

Introduction

Receptor activity-modifying proteins (RAMPs) consist, in mammals, of three single-pass transmembrane proteins, first identified as essential components of calcitonin gene-related peptide (CGRP) and adrenomedullin receptors (McLatchie *et al.*, 1998). They associate in the endoplasmic reticulum with a GPCR known as calcitonin receptor-like receptor (CLR). The RAMPs and CLR by themselves have poor abilities to reach the cell surface and cannot bind any known endogenous ligand. However, the complexes are translocated to the cell surface where they respond to CGRP, adrenomedullin and adrenomedullin 2 via CGRP, AM₁ and AM₂ receptors (Poyner *et al.*, 2002; Wootten *et al.*, 2010; Hong *et al.*, 2011). The trafficking of adrenomedullin receptors is also influenced by the RAMPs (Bomberger *et al.*, 2005).

RAMPs have subsequently been shown to interact with a wider range of GPCRs. The best characterized of these interactions is with the calcitonin receptor (CTR), where the RAMPs do not alter receptor cell surface expression but instead change ligand binding and G-protein coupling to give amylin receptors (Hay *et al.*, 2006; Morfis *et al.*, 2008). RAMPs 1 and 3 are needed for cell surface expression of the calcium sensing receptor, a glutamate-like/family C GPCR (Bouschet *et al.*, 2005). However, most interest has focussed on secretin-like/family B GPCRs. By monitoring the ability of GPCRs to increase the cell surface expression of RAMPs, it has been shown that the vasoactive intestinal polypeptide (VIP)/pituitary AC-activating peptide 1 receptor (VPAC₁) could interact with all three RAMPs, the parathyroid hormone PTH1 receptor could interact with RAMP2, the parathyroid hormone PTH2 receptor could interact with RAMP3 and the glucagon receptor could interact with RAMP2. No evidence was found for interactions between RAMPs and the VPAC₂ or either the GLP-1 or GLP-2 receptors (Christopoulos *et al.*, 2003). Only in the case of the VPAC₁ was there any characterization of the effects of RAMP association. The complex with RAMP2 had normal expression and pharmacology for activation of AC, but the maximum stimulation of phosphoinositide turnover in response to VIP was increased (Christopoulos *et al.*, 2003). It would seem unlikely that there is no consequence of RAMP association with these different receptors. Indeed, recent studies of *Ramp2*^{-/-} knockdown mice has shown there was a wide range of phenotypic changes that go far beyond what would be expected for effects mediated by peptides acting through CLR and CTR/RAMP complexes (Kadmiel *et al.*, 2011).

In this study, the ability of three family B GPCRs, the type 1 corticotrophin releasing factor receptor (CRF₁), the GLP-1 receptor and the VPAC₂ receptor to interact with all three RAMPs have been examined in HEK 293S and CHO-K1 cells. These receptors are of potential therapeutic interest. In evolutionary terms, the CRF₁ is the closest family B GPCR to the CTR and CLR (Fredriksson *et al.*, 2003), but its ability to interact with RAMPs has not previously been investigated. The VPAC₂ and GLP-1 receptor are on the other two main branches that make up secretin-like/family B GPCR family. The results show that the VPAC₂ can interact with all three RAMPs, and the CRF₁ can interact with RAMP2. These interactions differentially modulate G-protein coupling; in the case of the CRF₁, it is shown that this alters the pattern of

calcium signalling and furthermore, in *Ramp2*^{-/-} mice, the physiological effects of CRF on adrenal corticotrophic hormone (ACTH) release are reduced.

Methods

Materials

Peptides were from Bachem (St. Helens, UK). Unless otherwise specified, chemicals were from Sigma or Fisher (Loughborough, UK). Cell culture reagents were from Gibco BRL (Paisley, Renfrewshire, UK) or Sigma. Monoclonal anti-HA, mouse clone HA-7, monoclonal mouse anti-FLAG, clone M2 and monoclonal goat anti-mouse antibody containing a conjugated HRP were purchased from Sigma. G-protein antibodies (G_s, G_{q/11}, G_{12/13}, G_{i/o/t/z}) were from Santa Cruz (Santa Cruz, CA).

Expression constructs

Plasmid DNA was extracted from the cultures using a Wizard-Prep DNA extraction kit according to the manufacturer's instructions (Promega, Southampton, UK). The plasmid DNA was eluted in 100 µL sterile distilled water and stored at -20°C. For all receptors, a pcDNA3.1⁻ template vector was produced containing a T8 signal peptide and a HA-Tag (cloned in using *NotI* and *EcoRI*). The mature protein sequence for each receptor was then cloned in using *EcoRI* and *HindIII*. The *EcoRI* site between the tag, and the receptor sequence was removed using Quikchange. The RAMPs were modified with a FLAG tag inserted just before residue 24 (RAMP1), 42 (RAMP2) and 25 (RAMP3). A pcDNA3.1⁺ template vector was produced containing a CD33 signal peptide and a FLAG-Tag (cloned in using *HindIII* and *EcoRI*). The mature protein sequence for each RAMP was then cloned in using *EcoRI* and *XhoI*. The *EcoRI* site between the tag, and the RAMP sequence was removed using site mutagenesis with a Quikchange kit (Stratagene, Leicester, UK). The untagged constructs were in pcDNA3.1⁻ and were either gifts from AstraZeneca (receptors) or Dr Steve Foord, GSK-Wellcome (RAMPs). The CRF₁ receptor was isoform 1, which includes residues 147–176.

Cell culture and transfection

Cells were cultured in DMEM supplemented with 10% (v/v) FBS and 5% (v/v) penicillin/streptomycin in a humidified 95% air/5% CO₂ atmosphere. For transfection, the cells were plated onto either 12- and 48-well plates or 100 mm dishes. Cells were transfected using a mixture (per 1 µg DNA) of 6 µL 10 mM polyethylenimine and 45 µL 5% glucose solution incubated for 30 min at room temperature and added to an appropriate final volume of full media. Twelve- and 48-well plates were treated with 1 µg DNA per well, and 100 mm dishes were treated with 10 µg DNA per dish. The ratio of RAMP to receptor cDNA was 1:1 unless otherwise stated; where receptor or RAMP alone was transfected, the balance to 1 or 10 µg was made up with empty pcDNA3.1⁻ vector. Characterization of expressed receptors was performed 48–72 h after transfection.

Real-time quantitative PCR

Cells from confluent flasks were washed briefly with 1 mL cold PBS, detached with versene and pelleted by spinning at 350× *g* for 5 min. Total cellular RNA was isolated using the RNeasy kit and Qiashreder columns from Qiagen (Crawley, UK) following the manufacturer's recommendations. RNA isolated 48 h post transfection from HEK-293S cells and CHO-K1 cells transfected with cDNAs for human RAMP1, RAMP2 and RAMP3 were used as positive controls. RNA concentration was calculated based on the absorbance at 260 nm. cDNA was generated from 5 µg of total RNA by using the Promega Reverse Transcription System. Quantification of RAMP1, RAMP2 and RAMP3 expression was performed by a real-time PCR Roche lightcycler (Burgess Hill, UK) and the SYBER green I PCR kit for the lightcycler following the manufacturer's protocol. RAMP expression was standardized to the expression of the housekeeping gene GADPH.

Membrane preparation

Cells from 100 mm dishes were washed briefly with 1 mL cold PBS. They were detached with versene and pelleted by spinning at 350× *g* for 5 min at room temperature. The pellet was washed in ice-cold homogenization buffer (100 mM NaCl, 10 mM MgCl₂, 50 mM HEPES, pH 7.4), homogenized and then spun at 1700× *g* at 4°C for 10 min to pellet the nuclei. The supernatant was then respun at 40 000× *g* at 4°C for 90 min. The pellet was resuspended in homogenization buffer and stored at -80°C.

GTPγS binding

The binding reaction was set up on ice in 1.5 mL tubes in a final volume of 500 µL of assay buffer (10 mM NaCl, 10 mM MgCl₂, 0.2% BSA, 20 mM HEPES, pH 7.4) containing 150 µg membrane, 0.01% saponin and either 1 µM (for Gs) or 0.1 µM GDP (G_{12/13}, Gq/11 and G_{10/12}). After a 60 min preincubation at 30°C, 200 pM [³⁵S]-GTPγS was added and incubated for a further 30 min at 30°C. The reaction was terminated by adding 1 mL ice-cold assay buffer and centrifuged in a refrigerated microfuge at full speed for 6 min. The pellet was washed with 100 µL of ice-cold solubilization buffer (assay buffer with 1.25% NP40) and left on ice for 30 min to solubilise; 2 µg of the appropriate anti-Gα subunit antibody was added and incubated overnight at 4°C; 50 µL of 30% slurry of protein-A (pre-equilibrated in assay buffer) was added and left at 4°C for 90 min. After washing twice with 500 µL of cold 1× solubilization solution, the pellet was resuspended with 100 µL of solubilization buffer supplemented with 0.2% SDS and measured by scintillation counting.

Assay of cAMP production

Growth medium was removed from the cells and replaced with DMEM containing 500 µM isobutyl methyl xanthine for 30 min. Peptides in the range 10 pM to 1 µM were added for a further 15 min. Ice-cold ethanol (95–100% v/v) was used to extract cAMP, which was subsequently measured by radio-receptor assay as previously described (Poyner *et al.*, 1992). Data were normalized with respect to addition of 10 µM forskolin.

Measurements of intracellular Ca²⁺

Transfected cells were seeded in growth medium at 5 × 10⁴ cells per well in black, clear-bottomed, 96-well plates and

incubated overnight. Cells were washed with PBS, loaded with 100 µL per well of loading buffer (1X HBSS/20 mM HEPES/2 mM CaCl₂, pH 7.4) containing 5 mM probenecid and incubated at 37°C for 1 h. Fluorescence was determined using a FlexStation (Molecular Devices, Sunnyvale, CA) immediately after peptide ligand addition with excitation wavelength 485 nm and emission wavelength to 520 nm. Peak magnitude was determined using five-point smoothing, followed by correction against basal fluorescence.

Analysis of cell-surface expression by ELISA

Cells in 12-well plates were transiently transfected with receptors and RAMPs as appropriate. Details were as described previously (Conner *et al.*, 2005). The cells were treated with 250 µL of primary antibody (mouse, anti-HA antibody HA-7 or mouse anti-FLAG M2 [Sigma] diluted 1:2000 in PBS with 5% BSA) for 1 h.

Measurement of ACTH

Ramp2^{-/-} mice on an isogenic 129S6/SvEv genetic background have been previously described ((Dackor *et al.*, 2007; Kadmiel *et al.*, 2011). *Ramp2*^{-/-} (*n* = 6) and wild-type control (*n* = 8) mice were injected i.p. with CRF, (40 µg kg⁻¹, #H-2435, Bachem, Torrance, CA.) to stimulate release of ACTH. Blood samples were collected via sub-mandibular bleed after 2 h. An ultra-sensitive chemiluminescence ELISA kit (#MBSS80004, MyBioSource; San Diego, CA) was used according to the manufacturer's protocol to measure plasma levels of ACTH. Briefly, plasma samples were incubated a goat polyclonal antibody and a mouse monoclonal antibody to ACTH. One antibody is biotinylated and binds only the C-terminal of ACTH 34–39. The other antibody is labelled with HRP and binds only the mid-region and N-terminal of ACTH 1–24. The samples were then incubated with an enzyme-labelled antibody and a biotin coupled antibody in a streptavidin-coated microplate and analysed by addition of a luminal substrate. Concentrations of ACTH present in the controls and samples are determined from a standard curve and plotted as plasma ACTH (pg mL⁻¹). Experimental animals were 6–8 months of age, and control animals were wild-type, age- and gender-matched littermates. Animals were fed *ad libitum* and housed in standard 12 h/12 h light/dark cycle. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010). All experiments were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill.

Data analysis

Curve fitting was done with PRISM GraphPad 4 (GraphPad Software Inc., San Diego, CA). The data from each concentration–response curve were fitted to a sigmoidal concentration–response curve to obtain the maximum response and -logEC₅₀ (pEC₅₀). pEC₅₀, basal and maximal responses were compared by paired Student's *t*-test or by one-way ANOVA followed by Dunnett's test when multiple comparisons were made. Data from ELISAs were compared by the Mann–Whitney test. *n*-values refer to the number of independent experiments.

Results

Characterization of cell lines and receptors

As the effects of RAMPs are heavily influenced by cell line background (Tilakaratne *et al.*, 2000; Udawela *et al.*, 2006a), HEK 293S and CHO-K1 cells were both used in this study. They were first examined for expression of endogenous RAMPs by RT-PCR. The highest endogenous expression was that for RAMP2 in HEK 293S cells ($5.1 \pm 1.1\%$ of GAPDH expression); in all other cases, endogenous RAMP expression was not more than 2.25% of GAPDH. As an added check, both cell lines were transfected with CLR alone and challenged with either CGRP or adrenomedullin at concentrations from 0.01 to 1000 nM. In no case was there any detectable increase in cAMP. Thus, there was insufficient endogenous RAMP expression to generate CGRP, AM₁ or AM₂ receptors (Supporting Information Figures S1 and S2).

The pharmacology of N-terminal, HA-tagged CRF₁, CTR, GLP-1 receptor and VPAC₂ were compared with the untagged receptors, by measuring the ability of CRF, calcitonin, GLP-1(7–36)amide (GLP1) or VIP to stimulate cAMP production in cells transfected with their cognate receptor. In no case was there any difference in pEC₅₀, maximal or basal responses between the tagged and untagged receptors (Supporting Information Figure S3). Similarly, the properties of N-terminal FLAG-tagged RAMP1, 2 and 3 were compared with untagged RAMPs by co-transfecting with CLR and measuring the ability of either CGRP or adrenomedullin to stimulate cAMP at the resulting CGRP or adrenomedullin receptors. Again, there was no difference between the responses of the tagged and untagged RAMPs (Supporting Information Figure S4).

Cell surface expression of receptor–RAMP complexes

To investigate potential interactions between receptors and RAMPs, the ability of interacting receptors to increase cell surface RAMP expression was examined (Table 1) (Christopoulos *et al.*, 2003). As expected, cell surface expression of RAMPs transfected on their own was poor in both HEK 293S and CHO-K1 cells, but it was enhanced by co-transfection of the CTR. Co-transfection with GLP-1 receptor had no effect on RAMP expression. By contrast, VPAC₂ co-transfection sig-

nificantly enhanced the expression of all three RAMPs in both cell lines; the largest change was seen for RAMP1 whereas the increase with RAMP3 was much smaller. Co-transfection with CRF₁ enhanced cell surface expression of RAMP2 alone. In all cases, the enhancement of RAMP cell surface expression was greatest with the HEK 293S cells.

With both CLR and the calcium sensing receptor, there is a reciprocal interaction, whereby RAMPs also enhance the cell surface expression of the receptor (McLatchie *et al.*, 1998; Bouschet *et al.*, 2005). Accordingly, the ability of RAMPs to traffic the receptors to the cell surface was also examined (Table 2). Only RAMP2 had any effects, increasing the delivery of CRF₁. Consistent with the data on RAMP expression, the effect was larger in HEK 293S cells compared with CHO-K1 cells.

Effects on receptor pharmacology

The effects of RAMP expression on the pharmacology of the VPAC₂ and CRF₁ were investigated by examining the ability of a range of agonists to stimulate cAMP production. For the VPAC₂, the receptor was co-expressed with all three RAMPs in HEK 293S and CHO-K1 cells and challenged with VIP, BAY 55-9837, PACAP-27 and PHM-27 (Figure 1). These are all agonists at VIP/PACAP receptors with good potency against VPAC₂ receptors; BAY 55-9837 is selective for this subtype (Tsutsumi *et al.*, 2002). In no case was there any difference in the response of the receptors to the agonists. HEK 293S cells appeared to express an endogenous PAC₁ receptor, as the untransfected cells showed a good response to PACAP-27 (Figure 1B, pEC₅₀ 8.74 ± 0.09 , $E_{\max}$ $97 \pm 2\%$) and PHM-27 (Figure 1D; pEC₅₀ 8.60 ± 0.12 , $E_{\max}$ $62 \pm 2\%$). However, for VIP and BAY 55-9837 (Figure 1A, C) in these cells as well as for all four agonists in the CHO-K1 cells (Figure 1E–H), there was little response in untransfected cells so the lack of effect of the RAMPs was clear. There was a modest increase in basal cAMP production for the VPAC₁ receptor expressed with RAMP1 ($23.5 \pm 2.5\%$) and a slight decrease with RAMP3 ($-9.0 \pm 3.5\%$) compared with VPAC₁ alone ($8.0 \pm 2.1\%$) (Figure 1B, $P < 0.01$ and 0.05 , respectively, Dunnett's test following one-way ANOVA). For the CRF₁, the receptor was co-expressed with RAMP2 in HEK 293S cells and challenged with CRF, urocortin 1, and sauvagine (all agonists at the CRF₁ receptor) (Dautzenberg *et al.*, 2001). In addition, for CRF challenge, the receptor was also expressed with RAMP1 and RAMP3 (Figure 2). In no

Table 1

Cell surface expression of RAMPs in the presence or absence of receptors

RAMP	CTR	HEK 293S				CTR	CHO-K1			
		VPAC ₂	GLP-1R	CRF ₁	pcDNA3		VPAC ₂	GLP-1R	CRF ₁	pcDNA3
1	100	$69 \pm 5^*$	6 ± 1	2 ± 2	3 ± 2	100	$45 \pm 4^*$	2 ± 2	5 ± 2	2 ± 2
2	100	$62 \pm 6^*$	24 ± 3	$57 \pm 4^*$	22 ± 6	100	$36 \pm 7^*$	17 ± 3	$39 \pm 4^*$	15 ± 4
3	100	$49 \pm 5^*$	30 ± 8	27 ± 5	36 ± 4	100	$32 \pm 5^*$	13 ± 6	22 ± 6	19 ± 3

RAMPs were detected by cell surface ELISA of their FLAG tag. Expression was normalized (100%) to that seen when each RAMP was co-expressed with CTR. To determine receptor-independent expression, cells were co-transfected with the appropriate RAMP and empty vector (pcDNA3). Values are means $\pm$ SEM, $n > 3$.

*Expression significantly different from pcDNA3, $P < 0.05$, Mann–Whitney.

Table 2

Cell surface expression of receptors in the presence or absence of RAMPs

Receptor	HEK 293S				CHO-K1			
	pcDNA3	RAMP1	RAMP2	RAMP3	pcDNA3	RAMP1	RAMP2	RAMP3
CTR	100	104 ± 8	106 ± 7	108 ± 6	100	98 ± 5	107 ± 8	104 ± 9
VPAC ₂	100	105 ± 5	92 ± 3	83 ± 6	100	102 ± 6	95 ± 9	100 ± 6
GLP-1R	100	103 ± 4	98 ± 3	81 ± 5	100	101 ± 5	92 ± 7	79 ± 9
CRF ₁	100	94 ± 6	208 ± 16*	97 ± 7	100	95 ± 5	125 ± 7*	99 ± 11

Receptors were detected by cell surface ELISA of their HA tag. Expression was normalized (100%) to that seen in the absence of any RAMP [determined by cotransfecting with the appropriate receptor and empty vector (pcDNA3)]. Values are means ± SEM, *n* > 3.

*Expression significantly different from pcDNA3, *P* < 0.05, Mann–Whitney.

Table 3

Chief effects of RAMPs on the coupling of the VPAC₂ receptor to G-proteins

G-protein	Cells	RAMP	pEC ₅₀	E _{max}	Basal
G _{i/o/t/z}	HEK293S	No RAMP	6.79 ± 0.06	102.7 ± 2.8	1.3 ± 1.6
G _{i/o/t/z}	HEK293S	RAMP 1	7.37 ± 0.12*	106.6 ± 3.8	27.9 ± 2.7**
G _{i/o/t/z}	HEK293S	RAMP 2	7.45 ± 0.13*	123.0 ± 4.7	15.6 ± 3.7*
G _{i/o/t/z}	CHO-K1	No RAMP	7.01 ± 0.16	104.2 ± 4.2	-1.2 ± 2.8
G _{i/o/t/z}	CHO-K1	RAMP 1	7.29 ± 0.09	110.3 ± 2.9	21.7 ± 2.1**
G _{i/o/t/z}	CHO-K1	RAMP 2	7.05 ± 0.16	108.6 ± 6.1	17.9 ± 4.0**

Values are means ± SEM, *n* > 3.

*, **, *P* > 0.05, 0.01 or 0.001, relative to the parameter measured in the absence of a RAMP in the same cell line. Values compared using Dunnett's test following one-way ANOVA.

case was there any difference in the response of the receptors to the agonists. The experiments were also repeated in CHO-K1 cells with identical results (Supporting Information Figures S5 and S6).

GTPγS binding

To investigate if the RAMPs could modulate G-protein coupling, agonist-stimulated GTPγS binding to different G-proteins was investigated. For the VPAC₂, there was no effect on VIP-stimulated GTPγS binding to Gs (Figure 3). However, RAMP1 and RAMP2 significantly increased basal coupling to G_{i/o/t/z} in both cell lines (Table 3, Figure 4). RAMP1 in HEK 293S cells also gave a small increase in potency for VIP at stimulating this increase (Table 3, Figure 4A). RAMP3 had no effect on coupling to G_{i/o/t/z} in either cell line. There was no evidence of coupling of the VPAC₂ to either G_{q/11} or G_{12/13} in HEK 293S cells in the absence or presence of any of the three RAMPs (Supporting Information Figure S7).

RAMP2 had no effect on coupling of the CRF₁ to Gs in the presence of CRF. However, there was an enhanced coupling to G_{i/o/t/z}, G_{q/11} and G_{12/13} (Table 4, Figure 5). The differences depended on the G-protein. For G_{i/o/t/z} (Figure 5B), there was an enhancement of basal GTPγS binding and an increase in CRF-stimulated maximum response. For G_{q/11}, the main effect was an increase in the size of the CRF-stimulated maximum

response (Figure 5B). For G_{12/13}, the main effect was to increase the potency of CRF (Figure 5D). A very similar pattern was seen for urocortin (Figure 5E–H, Table 4).

As RAMP2 increases CRF₁ expression at the cell surface, there was a possibility that the enhanced GTPγS binding could be secondary to an increase in receptor number. Initially, the RAMP to receptor ratio was varied. If, instead of transfecting each well with 1 μg of plasmid containing DNA for the CRF₁, 0.6 μg was used, receptor expression was virtually reduced back to control values in the absence of RAMP2 (112 ± 6% of the expression of CRF₁ seen in the absence of RAMP2 measured by ELISA). The lower CRF₁ expression made little difference to the enhanced coupling seen to G_{i/o/t/z} in the presence of RAMP2 (Supporting Information Figure S8).

Enhanced Ca²⁺ elevation for CRF₁/RAMP2

The increased coupling seen to G_{q/11} and G_{i/o/t/z} suggested that RAMP2 should enhance CRF₁-mediated intracellular calcium mobilization. In HEK 293S cells there was a small elevation of intracellular Ca²⁺ in response to agonists in untransfected cells, suggesting low-level expression of an endogenous CRF receptor. However, the response became substantially larger following transfection with the CRF₁ and agonist potency also increased (Figure 6, Supporting Information Table S1). Transfection with RAMP2 enhanced the




Figure 1

Effects of RAMP co-transfection on the pharmacology of the VPAC₂ expressed in HEK 293S (A–D) and CHO-K1 cells (E–H). Cells were transiently transfected with either VPAC₂ + pcDNA3, VPAC₂ + RAMP1, VPAC₂ + RAMP2, VPAC₂ + RAMP3 or pcDNA3 alone. Values are normalized to the maximum response to forskolin when applied to the receptor alone. Values are means $\pm$ SEM, $n > 3$.




Figure 2

Effects of RAMP co-transfection on the pharmacology of the CRF₁ expressed in HEK 293S cells. Cells were transiently transfected with either CRF₁ + pcDNA3, CRF₁ + RAMP1, CRF₁ + RAMP2, CRF₁ + RAMP3 or pcDNA3 alone. Values are normalized to the maximum response to forskolin when applied to the receptor alone. Values are means $\pm$ SEM, $n > 3$.




Figure 3

VIP-stimulated GTPγS binding to Gαs in (a) HEK 293S and (b) CHO-K1 cells following transient transfection of either VPAC₂ + pcDNA3, VPAC₂ + RAMP1, VPAC₂ + RAMP2 or VPAC₂ + RAMP3. Values are means $\pm$ SEM, $n > 3$.

maximum response seen to CRF by $81 \pm 2\%$ and to urocortin by $64 \pm 2\%$ but had no effect on the response to sauvagine.

The mechanism responsible for the enhanced Ca²⁺ elevation was investigated by use of inhibitors (Table 5). In the absence of RAMP2, the elevated intracellular calcium appeared to be come entirely from an intracellular pool. Its release was blocked by the PLC inhibitor U73122, and the pool could be depleted by the CaATPase inhibitor thapsigargin. By contrast, in the presence of RAMP2, there was evidence for the use of extracellular Ca²⁺ in addition to this intracellular pool. Removal of extracellular Ca²⁺ reduced the response by about a one-third, and correspondingly, U73122 and thapsigargin only blocked about 2/3rd of the Ca²⁺ elevation. Pertussis toxin also inhibited the Ca²⁺ elevation by around a one-third. As its effects were additive with those of U73122 and thapsigargin but not with removal of extracel-




Figure 4

VIP-stimulated GTP γ S binding to G α i/o/t/z in (a) HEK 293S and (b) CHO-K1 cells following transient transfection of either VPAC₂ + pcDNA3, VPAC₂ + RAMP1, VPAC₂ + RAMP2 or VPAC₂ + RAMP3. Values are means $\pm$ SEM, $n > 3$.

lular Ca²⁺, it appears that the additional pool of extracellular Ca²⁺ is utilized via a G_{i/o/t/z}-mediated pathway.

CRF function in *Ramp2*^{+/-} mice

To further investigate whether there might be any physiological consequences of CRF₁/RAMP2 interactions, the ability of CRF to increase plasma levels of ACTH was compared in normal and *Ramp2*^{+/-} mice (Kadmiel *et al.*, 2011). Two hours after CRF administration, the plasma ACTH concentration in the *Ramp2*^{+/-} animals was significantly reduced to levels that were roughly 20% lower than similarly treated wild-type control animals (Figure 7).

Discussion and conclusions

This study has demonstrated the coupling of two family B GPCRs to RAMPs additional to those previously known. The

VPAC₂ can interact with all three RAMPs; for RAMPs 1 and 2, this leads to enhanced coupling to G_{i/o/t/z}. The CRF₁ interacts with RAMP2 leading to enhanced CRF₁ expression at the cell surface and increased coupling to G_{i/o/t/z}, G_{q/11} and G_{12/13}. The G_{i/o/t/z} coupling results in extracellular Ca²⁺ entry following challenge with CRF. RAMP2 association also reveals differences in the ability of CRF and urocortin on the one hand and sauvagine on the other to increase intracellular calcium.

This study provides further evidence of the importance of the cell line background in modulating the effects of RAMPs. In the current study, the responses resulting from RAMP interactions were consistently larger using HEK 293S compared with CHO-K1 cells. In addition, a previous study investigating RAMP interactions revealed no association with the VPAC₂ (Christopoulos *et al.*, 2003). Thus, care is needed in interpreting negative data when investigating RAMP effects. However, it is striking that the failure of the GLP1 receptor to associate with any RAMP has now been observed in three cell lines, consistently supporting the conclusion that it has very little, if any, ability to associate with these proteins.

The diversity of RAMP effects are clearly illustrated in this study. Only for CRF₁ was there an effect on cell surface expression. A more general effect was to promote differential G-protein coupling. This has previously been observed, for the VPAC₁ and the CTR (Christopoulos *et al.*, 2003; Morfis *et al.*, 2008). In the case of the CTR, RAMP2 enhanced Gs association whereas RAMP3 enhanced both Gs and Gq (Morfis *et al.*, 2008). In the current study, it appears that the mechanism of enhancement depends on the individual RAMP and the G-protein. Enhanced coupling of G_{i/o/t/z} was observed to both the VPAC₂ and the CRF₁, and in all cases, the main effect was an increase in basal G-protein activation. This implies that the RAMP enhances baseline activity of both receptors. With RAMP2, for both receptors when expressed in HEK 293S cells, there was also an increase in the maximum response, implying a greater number of active receptor-Gi complexes; this mirrors the effect noted for the VPAC₁: RAMP2 complex on enhanced phosphoinositide breakdown (Christopoulos *et al.*, 2003). The simplest interpretation is that by some mechanism, the RAMP increases the accessibility of the receptor to the G-protein (Morfis *et al.*, 2003). This effect was cell line-dependent as it was not seen in the CHO-K1 cells. RAMP2 also enhanced coupling between the CRF₁ and G_{q/11} and G_{12/13}, but the mechanisms appeared to be different. For G_{q/11}, the maximum response was increased, suggesting an increased number of receptor-G_{q/11} complexes. For G_{12/13}, the main effect was an increase in potency of both CRF and a second agonist, urocortin 1. This implies an increased affinity for the G-protein. A small increase in potency for VIP was noted with G_{i/o/t/z} in HEK 293S cells, although as there was also an increase in maximum response, this might in part at least be due to increased accessibility of the G-protein to the receptor. Regardless of this, it appears that there are multiple mechanisms by which RAMPs can modulate G-protein coupling.

The RAMP effects also depend on the nature of the agonist. With CRF₁, the calcium response to CRF and urocortin 1 was enhanced whereas this was not observed with sauvagine. Differential enhancement of agonist potency has been observed at amylin receptors, where RAMP1 association selectively increases the potency of CGRP at stimulating AC

Table 4

Effects of RAMP 2 on the coupling of the CRF₁ receptor to G-proteins

Agonist	G-protein	pEC ₅₀	E _{max}	Basal	pEC ₅₀	E _{max}	Basal
		No RAMP			RAMP 2		
CRF	Gs	7.28 ± 0.13	98.1 ± 5.0	6.1 ± 5.0	7.12 ± 0.15	92.0 ± 4.3	9.5 ± 6.3
Urocortin	Gs	7.56 ± 0.16	109.9 ± 6.4	-8.2 ± 5.3	7.45 ± 0.14	113.7 ± 5.9	-9.8 ± 4.7
CRF	Gi/o/t/z	6.97 ± 0.08	98.8 ± 4.7	3.8 ± 2.7	7.29 ± 0.31	269.1 ± 26.2**	65.3 ± 17.6*
Urocortin	Gi/o/t/z	7.25 ± 0.16	96.4 ± 5.7	-0.6 ± 4.1	7.41 ± 0.14	288.1 ± 10.7***	67.0 ± 8.3***
CRF	Gq	7.48 ± 0.90	82.5 ± 27.4	4.2 ± 21.8	7.56 ± 0.26	270.4 ± 28.2**	-3.7 ± 22.4
Urocortin	Gq	6.99 ± 0.35	105.2 ± 14.5	5.9 ± 9.4	7.23 ± 0.13	291.3 ± 12.4***	38.7 ± 8.8
CRF	G ₁₂	5.93 ± 0.19	107.4 ± 16.4	6.40 ± 3.2	7.57 ± 0.24**	138.4 ± 12.8	-3.4 ± 9.4
Urocortin	G ₁₂	6.24 ± 0.29	105.6 ± 15.0	6.1 ± 3.1	7.57 ± 0.14*	176.4 ± 7.3*	17.6 ± 6.1

Values are means ± SEM, $n > 3$. *, **, *** $P > 0.05$, 0.01 or 0.001, relative to the parameter measured in the absence of RAMP 2 in the same cell line. Values compared using by Student's *t*-test.

Table 5

Inhibition of Ca²⁺ mobilization in response to activation of the CRF₁

Inhibitors	% Inhibition of Ca ²⁺ response following stimulation by 1 μM CRF	
	CRF ₁	CRF ₁ + RAMP 2
None	0	0
+ U73122	99 ± 2*	76 ± 3*
+ Thapsigargin	98 ± 3*	72 ± 4*
+ PTx	12 ± 8	32 ± 7*
+PTx + U73122	100 ± 4	100 ± 1*
+ CTx	9 ± 5	6 ± 3
- Ca ²⁺	0 ± 5	31 ± 8*
- Ca ²⁺ + U73122	100 ± 1*	100 ± 1*
- Ca ²⁺ + Thapsigargin	100 ± 1*	99 ± 4*
- Ca ²⁺ + PTx	9 ± 2	41 ± 5*

Intracellular calcium was measured as described in Methods. Values are means ± SEM, $n > 3$.


*Inhibition significantly different from 0%, $P < 0.05$, Mann-Whitney.

(Udawela *et al.*, 2006b). It has been established that distinct conformations of the CRF₁ are involved in coupling to Gs and Gi (Berger *et al.*, 2006) and bias in agonist-signalling has been observed at the CRF₁ (Ruhmann *et al.*, 1999; Grammatopoulos *et al.*, 2000; Beyermann *et al.*, 2007; Grammatopoulos, 2012). Thus, in HEK 293S cells, sauvagine and urocortin are equipotent at promoting GTPγS binding to Gs but urocortin is more potent on G_{i/o/t/z}. Furthermore, it is possible to discriminate between urocortin- and sauvagine-mediated increases in GTPγS binding using antagonists (Berger *et al.*, 2006). Thus there is good evidence that the two agonists

promote different conformations of the CRF₁, and this could explain the different Ca²⁺ responses revealed after RAMP2 transfection.

The interactions between the VPAC₂ and CRF₁ and the different RAMPs are potentially of physiological importance. In the case of the CRF₁ receptor, this study has shown that the alterations in G-protein coupling cause changes in the pattern of calcium mobilization in transfected cells and that in mice, a genetic reduction in RAMP2 reduces the ability of CRF to stimulate ACTH release. The ability of the CRF₁ to increase intracellular calcium (and especially the role of extracellular calcium in that process) is known to be cell-type-dependent (Soares *et al.*, 2005; Gutknecht *et al.*, 2008); the presence of RAMP2 may be one factor behind this. CRF stimulation of ACTH release is of pivotal importance to the role of this hormone (Bale and Vale, 2004). The mechanism by which RAMP2 modulates this response remains to be established as this effect is normally considered to be mediated via cAMP (Reisine *et al.*, 1985), and no effect was observed on this second messenger in the current study. As the effects of RAMPs are cell-line-dependent, this may be less of a paradox than first appears. Whatever the explanation, the observation of reduced CRF responsiveness is consistent with the RAMP2-CRF₁ interaction being relevant *in vivo*. Given that the animals are only heterozygote for RAMP2, the reduction seen in ACTH levels may underestimate the real contribution of RAMP2 association to enhancing the response to CRF.

Comparison of the distribution of the VPAC₂ and CRF₁ receptors and the relevant RAMPs show there is potential for co-expression *in vivo*. For CRF₁ mRNA, there is overlap with the reported distribution of RAMP2 mRNA in several rat brain structures including the dentate gyrus, the CA1 and 3 regions of the hippocampus, various regions of the amygdala, some cortical layers and the dorsomedial hypothalamus (Potter *et al.*, 1994; Oliver *et al.*, 2001). There is also reported to be co-expression of mRNA and/or protein in human adipocytes (Seres *et al.*, 2004; Silaghi *et al.*, 2007) and cerebral arteries, albeit based on a rat-human comparison (Oliver *et al.*, 2002;

**Figure 5**

CRF- (a-d) and urocortin- (e-h) stimulated GTP γ S binding to (A and E) G α s, (B and F) G α i, (C and G) G α q and (D and H) G α 12 in HEK 293S cells following transfection with CRF₁+ pcDNA3 and CRF₁+ RAMP2. Values are means $\pm$ SEM of $n = 3$.




Figure 6

Effect of RAMP2 on (a) CRF-induced, (b) Urocortin1-induced and (c) sauvagine-induced Ca^{2+} mobilization in HEK 293S cells transfected with either CRF₁ + pcDNA3, CRF₁ + RAMP2 or pcDNA3 alone. Values are normalized to the maximum response produced by ATP. Values are means $\pm$ SEM, $n = 3$.




Figure 7

ACTH response to CRF in wild-type and Ramp2^{+/-} mice. Male mice were injected with 40 mg kg⁻¹ CRF and plasma was collected 2 h later. Plasma ACTH levels were measured by chemiluminescence ELISA. Wild-type ACTH 156 $\pm$ 47 pg mL⁻¹; Ramp2^{+/-} ACTH 124 $\pm$ 22 pg mL⁻¹. Error bars represent SEM, $n = 6$ –8. Values were compared by Student's *t*-test.

Deussing *et al.*, 2007). For the VPAC₂, there are overlapping distributions of the receptor with RAMPs 1 and 2 in similar regions of rat brain to the CRF (Joo *et al.*, 2004). In the periphery, there are common distribution patterns in many types of smooth muscle, especially vascular smooth muscle (Knutsson and Edvinsson, 2002). These studies are no more than suggestive; ultimately it will be necessary to show co-localization of the relevant components in the same cells. However, the current data suggest further work in this area would be useful.

In conclusion, this work demonstrates the interaction of RAMPs with two additional GPCRs. It suggests that RAMPs can enhance G-protein interactions. These interactions can have measurable consequences for cell signalling and for CRF *in vivo* responsiveness.

Acknowledgements

We would like to thank AZ for financial support, Britt-Marie Kihlberg for experimental assistance and Drs Dave Smith and John Simms for scientific discussions. Portions of this study were supported by US NIH grants HL091973 and HD060860 to KMC.

Conflict of interest

None.

References

Bale TL, Vale WW (2004). CRF and CRF receptors: role in stress responsiveness and other behaviors. *Annu Rev Pharmacol Toxicol* 44: 525–557.

- Berger H, Heinrich N, Wietfeld D, Bienert M, Beyermann M (2006). Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain. *Br J Pharmacol* 149: 942–947.
- Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W, Kraetke O *et al.* (2007). Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain. *Br J Pharmacol* 151: 851–859.
- Bomberger JM, Spielman WS, Hall CS, Weinman EJ, Parameswaran N (2005). Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1. *J Biol Chem* 280: 23926–23935.
- Bouschet T, Martin S, Henley JM (2005). Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. *J Cell Sci* 118 (Pt 20): 4709–4720.
- Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A *et al.* (2003). Novel receptor partners and function of receptor activity-modifying proteins. *J Biol Chem* 278: 3293–3297.
- Conner AC, Hay DL, Simms J, Howitt SG, Schindler M, Smith DM *et al.* (2005). A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors. *Mol Pharmacol* 67: 20–31.
- Dackor R, Fritz-Six K, Smithies O, Caron K (2007). Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. *J Biol Chem* 282: 18094–18099.
- Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G (2001). Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences. *J Pharmacol Exp Ther* 296: 113–120.
- Deussing JM, Kuhne C, Putz B, Panhuysen M, Breu J, Stenzel-Poore MP *et al.* (2007). Expression profiling identifies the CRH/CRH-R1 system as a modulator of neurovascular gene activity. *J Cereb Blood Flow Metab* 27: 1476–1495.
- Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol Pharmacol* 63: 1256–1272.
- Grammatopoulos DK (2012). Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. *Br J Pharmacol* 166: 85–97.
- Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hillhouse EW (2000). Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. *Mol Endocrinol* 14: 2076–2091.
- Gutknecht E, Van der Linden I, Van Kolen K, Verhoeven KF, Vauquelin G, Dautzenberg FM (2008). Molecular mechanisms of corticotropin releasing factor receptor-induced calcium signaling. *Mol Pharmacol* 75: 648–657.
- Hay DL, Poyner DR, Sexton PM (2006). GPCR modulation by RAMPs. *Pharmacol Ther* 109: 173–197.
- Hong Y, Hay DL, Quirion R, Poyner DR (2011). The pharmacology of Adrenomedullin 2/Intermedin. *Br J Pharmacol* 166: 110–120.
- Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH *et al.* (2004). Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. *J Comp Neurol* 476: 388–413.
- Kadmiel M, Fritz-Six K, Pacharne S, Richards GO, Li M, Skerry TM *et al.* (2011). Research resource: haploinsufficiency of receptor activity-modifying protein-2 (RAMP2) causes reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine dysfunction in mice. *Mol Endocrinol* 25: 1244–1253.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. *Br J Pharmacol* 160: 1577–1579.
- Knutsson M, Edvinsson L (2002). Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. *Neuroreport* 13: 507–509.
- McGrath J, Drummond G, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. *Br J Pharmacol* 160: 1573–1576.
- McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N *et al.* (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* 393: 333–339.
- Morfis M, Christopoulos A, Sexton PM (2003). RAMPs: 5 years on, where to now? *Trends Pharmacol Sci* 24: 596–601.
- Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, Christopoulos A *et al.* (2008). Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. *Endocrinology* 149: 5423–5431.
- Oliver KR, Kane SA, Salvatore CA, Mallee JJ, Kinsey AM, Koblan KS *et al.* (2001). Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat. *Eur J Neurosci* 14: 618–628.
- Oliver KR, Wainwright A, Edvinsson L, Pickard JD, Hill RG (2002). Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. *J Cereb Blood Flow Metab* 22: 620–629.
- Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K *et al.* (1994). Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. *Proc Natl Acad Sci USA* 91: 8777–8781.
- Poyner DR, Andrew DP, Brown D, Bose C, Hanley MR (1992). Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes. *Br J Pharmacol* 105: 441–447.
- Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W *et al.* (2002). International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. *Pharmacol Rev* 54: 233–246.
- Reisine T, Rougon G, Barbet J, Affolter HU (1985). Corticotropin-releasing factor-induced adrenocorticotropin hormone release and synthesis is blocked by incorporation of the inhibitor of cyclic AMP-dependent protein kinase into anterior pituitary tumor cells by liposomes. *Proc Natl Acad Sci USA* 82: 8261–8265.
- Ruhmann A, Bonk I, Kopke AK (1999). High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1. *Peptides* 20: 1311–1319.
- Seres J, Bornstein SR, Seres P, Willenberg HS, Schulte KM, Scherbaum WA *et al.* (2004). Corticotropin-releasing hormone system in human adipose tissue. *J Clin Endocrinol Metab* 89: 965–970.

Silaghi A, Achard V, Paulmyer-Lacroix O, Scridon T, Tassistro V, Duncea I *et al.* (2007). Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status. *Am J Physiol Endocrinol Metab* 293: E1443–E1450.

Soares SM, Thompson M, Chini EN (2005). Role of the second-messenger cyclic-adenosine 5'-diphosphate-ribose on adrenocorticotropin secretion from pituitary cells. *Endocrinology* 146: 2186–2192.

Tilakaratne N, Christopoulos G, Zumpfe ET, Foord SM, Sexton PM (2000). Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. *J Pharmacol Exp Ther* 294: 61–72.

Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J *et al.* (2002). A potent and highly selective VPAC₂ agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. *Diabetes* 51: 1453–1460.

Udawela M, Christopoulos G, Morfis M, Christopoulos A, Ye S, Tilakaratne N *et al.* (2006a). A critical role for the short intracellular C terminus in receptor activity-modifying protein function. *Mol Pharmacol* 70: 1750–1760.

Udawela M, Christopoulos G, Tilakaratne N, Christopoulos A, Albiston A, Sexton PM (2006b). Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. *Mol Pharmacol* 69: 1984–1989.

Wootten DL, Simms J, Hay DL, Christopoulos A, Sexton PM (2010). Receptor activity modifying proteins and their potential as drug targets. *Prog Mol Biol Transl Sci* 91: 53–79.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1 Failure of HEK 293 cells transfected with CLR alone to respond to CGRP or adrenomedullin (ADM). Values are means $\pm$ range of duplicate determinations from a single experiment.

Figure S2 Failure of CHO-K1 cells transfected with CLR alone to respond to CGRP or ADM. Values are means $\pm$ range of duplicate determinations from a single experiment.

Figure S3 Effects of epitope tags on the VPAC₂, GLP-1, CRF₁ and CT receptors transiently expressed in CHO-K1 cells. Values are means $\pm$ SD, $n = 2$.

Figure S4 Effects of epitope tags on the pharmacology of CGRP, AM₁ or AM₂ receptors expressed in HEK-293 cells. Number indicates the residue in the RAMP to which the FLAG tag was attached. Values are means $\pm$ SEM from three independent experiments.

Figure S5 Pharmacology of VPAC₂ receptor transfected with RAMPs in CHO-K1 cells. Values are means $\pm$ SEM from three independent experiments.

Figure S6 Pharmacology of CRF₁ receptor transfected with RAMP2 in CHO-K1 cells. Values are means $\pm$ SEM determined from three independent experiments performed in duplicate.

Figure S7 GTP γ S stimulation mediated by the VPAC₂ in the presence or absence of RAMPs in HEK293 cells. Top; stimulation of binding to G_{12/13}. Bottom, stimulation of binding to Gq/G₁₁. A small signal was detected but this was also observed in a RAMP1 only transfection. Experiments are representative of three. Values are means $\pm$ SEM of three independent experiments performed in duplicate.

Figure S8 Effects of varying CRF1R cDNA concentration on CRF-stimulated GTP γ S to Gi in HEK 293S cells. Values are normalized to the maximum response seen in cells transfected with CRF1R alone. Values are means $\pm$ SEM of three independent experiments performed in duplicate.

Table S1 Effects of RAMP2 on the CRF₁-mediated elevation in intracellular calcium in HEK 293S cells.